<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6459">
  <stage>Registered</stage>
  <submitdate>16/11/2012</submitdate>
  <approvaldate>16/11/2012</approvaldate>
  <nctid>NCT01730807</nctid>
  <trial_identification>
    <studytitle>IntellaTip MiFi XP Ablation Catheter Trial</studytitle>
    <scientifictitle>IntellaTip MiFi XP Ablation Catheters First in Human Use Trial</scientifictitle>
    <utrn />
    <trialacronym>MiFi-CTI</trialacronym>
    <secondaryid>MiFi-CTI</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Atrial Flutter</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - IntellaTip MiFi XP Catheter

Experimental: IntellaTip XP MiFi - Patients with Atrial Flutter will receive ablation treatment with the IntellaTip MiFi XP catheter


Treatment: devices: IntellaTip MiFi XP Catheter
Temperature controlled ablation catheter

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Acute Procedural Success - The Demonstration of bi-directional isthmus block at the end of the ablation procedure</outcome>
      <timepoint>one day</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Complication Rate at procedure - Determine major complications in patients exposed to the device, which occur within 7 days of the procedure</outcome>
      <timepoint>7 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  18 or older

          -  indicated for ablation for Atrial Flutter</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Thrombus

          -  Recent MI/cardiac revascularization

          -  Prosthetic Valves

          -  recent ablation for atrial flutter

          -  atrial flutter with reversible cause

          -  Class IV HF</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>10</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <postcode>5001 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boston Scientific Corporation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A study to assess the performance of a new catheter design for the treatment of Atrial
      Flutter.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01730807</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prashanthan Sanders, MD</name>
      <address>Royal Adelaide Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>